Merck Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights ...
DARMSTADT, Germany, Dec. 20, 2018 /PRNewswire-AsiaNet/ -- Not intended for distribution in the USA, Canada or UK- Agreement enables Merck to maintain an investment in the rapidly advancing oncology field of CAR-T, while focusing its R&D efforts- Intrexon to issue Merck $150 millio...
Read more https://view-release/?pr-id=76861